Kazia Therapeutics (KZIA) Change in Accured Expenses (2019 - 2022)

Kazia Therapeutics (KZIA) has 3 years of Change in Accured Expenses data on file, last reported at -$89056.7 in Q4 2022.

• In Q4 2022, Change in Accured Expenses changed N/A year-over-year to -$89056.7; the TTM figure through Dec 2022 stood at $1.4 million (changed N/A YoY), while the FY2012 annual figure was -$698745.8, down 665.32% from the prior year.
• Change in Accured Expenses rose to -$89056.7 in Q4 2022, from -$108980.9 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at -$89056.7 in Q4 2022 and bottomed at -$108980.9 in Q4 2020.
• A 3-year average of -$99966.6 and a median of -$101862.1 in 2019 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 6.99% in 2020, down 6.99% in 2020.
• Year by year, Change in Accured Expenses stood at -$101862.1 in 2019, then fell by 6.99% to -$108980.9 in 2020, then grew by 18.28% to -$89056.7 in 2022.
• The last three Change in Accured Expenses figures came in at -$89056.7 (Q4 2022), -$108980.9 (Q4 2020), and -$101862.1 (Q4 2019), per Business Quant data.

Peer Comparison